RxDoctor Payments Data

Katherine Shaffer, MD

Gastroenterology · San Diego, CANPI 1336405695

Payments from drug & device makers

$2,102in general payments, 2019–2025

Across 112 payments — averaging $18.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Nestle Healthcare Nutrition Inc.$249
  • Pfizer$231
  • Sanofi-aventis U.S. LLC$116
  • Intercept Pharmaceuticals, Inc.$54
  • Takeda Pharmaceuticals U.S.A., Inc.$48
  • plus $181 from 6 others

What the payments were for

  • Food & beverage$2,102100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,102 in reported general payments places this provider in the 50th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$32,271
Medicare patients
117
Services billed
211

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin25$72,007
LinzessLinaclotide64$34,576
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates53$3,309
Mesalamine14$3,071
Omeprazole292$2,875
Mesalamine ErMesalamine13$2,387
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl95$2,134
Pantoprazole Sodium48$595
Hydrocortisone18$494
Desipramine Hcl11$419
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl24$393
Lactulose12$369
Famotidine44$268
LoperamideLoperamide Hcl29$205
Metronidazole14$106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,223$34,57664 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →